LY3437943 · Triple G
Triple agonist (GLP-1/GIP/Glucagon) — next-gen weight loss.
FDA
Research Only
WADA
Not Listed
HALF-LIFE
~6 days
ROUTE
SubQ injection (weekly)
SCHEDULE
Once weekly
In Plain English
Triple agonist (GLP-1/GIP/Glucagon) — next-gen weight loss.
Status & Legality
NATTY?
No Test ExistsNo established test exists for this compound.
FDA
Research OnlyFor research purposes only. Not FDA approved.
WADA
Not ListedNot currently on WADA prohibited list.
COMPOUNDING
Not from pharmaciesNot available from licensed compounding pharmacies.
PRESCRIBED
Not prescribedNot prescribed in conventional medicine.
ROUTE
SubQ injection (weekly)Administration via subq injection (weekly).
Weight loss
Metabolic syndrome
NASH/MASH liver disease
Retatrutide is a triple G agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed up to 24.2% body weight reduction — exceeding any currently approved therapy. The glucagon component adds hepatic fat reduction and energy expenditure, making it distinct from dual agonists.
Nausea
Vomiting
Diarrhea
Decreased appetite
Fatigue
Eructation (burping)
Dosing like semaglutide — retatrutide is more potent and requires far more conservative titration
Using without close medical supervision — the triple agonist mechanism makes glucose and cardiovascular effects harder to predict
Sourcing from unverified compounding sources — quality control for a Phase 3 drug compound is critical
Insulin and diabetes medications — significant hypoglycemia risk from the combined GLP-1/GIP/glucagon action
Antihypertensives — the glucagon component adds blood pressure effects; monitor closely
Warfarin — monitor INR during active weight loss; absorption changes affect many drugs
Retatrutide looks like the most powerful weight loss peptide to date — 24%+ average reduction in Phase 2 trials. The glucagon component makes it uniquely effective for hepatic fat and energy expenditure beyond what GLP-1 alone achieves. Still in trials; compounded versions require careful sourcing and extremely conservative titration.
Stats
Sources & Studies
Rosenstock J. et al., Lancet, 2023